<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Verbaan, D.</title>
    <link>http://repub.eur.nl/res/aut/59312/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/37149/</link>
      <pubDate>2012-01-01T00:00:00Z</pubDate>
      <description>Background:: The A-allele of the catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with decreased enzymatic activity and higher dopamine availability. Methods:: We studied 219 patients with PD who were free of dyskinesias at baseline and underwent thorough annual examinations. Results:: The A-allele of the COMT Val158Met polymorphism was related to an increased risk of developing dyskinesias during follow-up, in a dose-dependent manner (adjusted hazard ratios for the AG and AA genotypes [compared to GG]: 2.09 [95% confidence interval (CI), 1.07-4.06] and 2.81 [CI, 1.43-5.54], respectively). Conclusions:: This finding suggests that genetic factors may affect susceptibility to dyskinesias in PD. </description>
    </item>
  </channel>
</rss>